Benefits
Hot flashes: tested only inside multi-herb formulas
Zhi Mu on its own has never been tested for hot flashes in a published human trial. It is one of six herbs in Er-Xian decoction, which beat placebo over 12 weeks in 108 Hong Kong perimenopausal women, though the placebo group improved almost as much: the hot flush score fell from 16.6 to 7.0 on placebo versus 19.6 to 4.9 on the formula (P = 0.02). A four-arm pilot trial of a formula named Zhi Mu 14, with about 10 women per arm, found no difference from placebo on hot flush frequency, severity or Menopause Rating Scale score. The 2016 Cochrane review of Chinese herbal medicine for menopausal symptoms (22 trials, 2,902 women) pooled the placebo-controlled trials that counted hot flushes per day and found little or no difference (mean difference 0.00 per day, 95% CI -0.88 to 0.89, from 2 trials in 199 women). Nothing measured for a multi-herb formula can be credited to Anemarrhena alone.
Cognition: the one human trial of its aglycone found no benefit
Sarsasapogenin, the aglycone from this rhizome, was tested at 200 mg/day for 8 weeks against placebo in 80 patients already taking risperidone. Memory (Wechsler Memory Scale) and intelligence (modified Chinese Wechsler Adult Intelligence Scale) scores did not differ from placebo. Improved maze performance in aged and scopolamine-treated rodents is the whole basis for the cognitive interest in this herb, and it did not carry over to the one human test that has been run.
Blood glucose: rodent data only, never tested in people
Mangiferin and timosaponins lower blood glucose in diabetic rodents. No trial has given Anemarrhena rhizome or its extract to people to see whether glucose changes at all. The closest human data come from isolated mangiferin at 150 mg/day for 12 weeks in 97 overweight adults with high blood lipids: triglycerides and free fatty acids fell and the insulin resistance index improved, but fasting glucose and insulin themselves did not differ from placebo. Mangiferin also occurs in mango leaf and other plants, so that trial is not a test of this rhizome.
Inflammatory signaling: cell and animal models only
Timosaponins and mangiferin suppress NF-κB activation and lower TNF-alpha and IL-6 output in cultured cells and in rodents. No inflammatory marker has been measured in people taking Anemarrhena, so this remains a laboratory finding. The traditional use for 'clearing heat' is a TCM concept, not an inflammation measurement.
Antioxidant activity in laboratory assays
Mangiferin is a well-characterized antioxidant xanthone in test-tube assays and raises antioxidant enzyme activity in animals. It is also the main xanthone in mango leaf and several other plants, so most of the antioxidant literature attached to this rhizome is really literature on mangiferin. No antioxidant or oxidative-stress marker has been measured in people taking Anemarrhena.
Mechanism of action
Cholinergic and BDNF modulation
Preclinical studies suggest sarsasapogenin enhances cholinergic neurotransmission and supports brain-derived neurotrophic factor (BDNF) expression. These are rodent and cell-culture findings. The one human trial of sarsasapogenin measured memory directly and found no difference from placebo.
Insulin sensitivity and glucose handling
Mangiferin from Anemarrhena has been shown to activate AMPK signaling and modulate PPARγ in animal models, contributing to improved insulin sensitivity and reduced hepatic glucose output, supporting balanced glucose metabolism.
NF-κB and cytokine modulation
Timosaponins suppress NF-κB activation and reduce production of pro-inflammatory cytokines such as TNF-α and IL-6 in cell models, contributing to the herb's traditional reputation for 'cooling' inflammatory conditions.
Thermoregulatory and HPA-axis effects
Animal research suggests Anemarrhena extracts may modulate hypothalamic temperature regulation and HPA-axis activity, providing a plausible mechanism for traditional use in addressing hot flashes and stress-related heat symptoms.
Clinical trials
Randomized, double-blind, placebo-controlled trial, 12 weeks, of Er-Xian decoction, a six-herb formula whose ingredients include Rhizoma Anemarrhenae and Cortex Phellodendri alongside Rhizoma Curculiginis, Herba Epimedii, Radix Morindae Officinalis and Radix Angelicae Sinensis. Zhong LL et al., Menopause 2013;20(7):767-76 (PMID 23793167).
108 Hong Kong PERImenopausal women with a Menopause Rating Scale total score of 28 or higher; 101 completed the study.
Hot flush frequency fell from 5.8 to 2.2 per day on the formula and from 5.0 to 2.4 on placebo (P = 0.04). The hot flush score fell from 19.6 to 4.9 versus 16.6 to 7.0 on placebo (P = 0.02). Menopause Rating Scale and menopause-specific quality-of-life scores also favored the formula, serum hormone levels did not change, and blood counts, liver and kidney tests stayed normal. Most of the improvement happened in the placebo group too, and five of the six herbs were not Anemarrhena, so nothing here can be attributed to this rhizome.
Double-blind, placebo-controlled, parallel-group trial of sarsasapogenin, the aglycone from Anemarrhena, at 200 mg/day for 8 weeks added to risperidone 2 to 4 mg/day. Xiao SF et al., Neuroscience Bulletin 2011;27(4):258-68 (PMID 21788997).
80 adults with negative-symptom-dominant schizophrenia (41 on sarsasapogenin, 39 on placebo).
Sarsasapogenin produced no significant difference from placebo on the Positive and Negative Syndrome Scale, the Wechsler Memory Scale or the modified Chinese Wechsler Adult Intelligence Scale at 8 weeks. Adverse events matched placebo, so 200 mg/day was safe and well tolerated but did not improve memory, intelligence or symptoms. Sarsasapogenin is one isolated aglycone, not the whole rhizome.